Inventor · disambiguated record
Zhenwu Li
Also filed as: LI ZHENWU
13 granted patents·15 pending applications·104 citations·filing 2015–2024
90Inventor score
Top patents by PatentIndex Score
28 records- 0198US11608337B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Mar 21, 2023·15 cites·22 claims
- 0298US11407749B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 9, 2022·23 cites·24 claims
- 0397US9944647B2Heterocyclic compounds as LSD1 inhibitorsINCYTE CORP·Filed 2016·Granted Apr 17, 2018·30 cites·12 claims
- 0495US11596692B1PD-L1/STING conjugates and methods of useINCYTE CORP·Filed 2019·Granted Mar 7, 2023·12 cites·40 claims
- 0594US11713317B2Tricyclic heterocyclic compounds as sting activatorsINCYTE CORP·Filed 2021·Granted Aug 1, 2023·3 cites·39 claims
- 0694US11472791B2Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Oct 18, 2022·7 cites·31 claims
- 0793US11851426B2Bicyclic amines as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Dec 26, 2023·3 cites·20 claims
- 0892US10800779B2Heterocyclic compounds as LSD1 inhibitorsINCYTE CORP·Filed 2018·Granted Oct 13, 2020·6 cites·34 claims
- 0990US10947227B2Tricyclic heterocyclic compounds as sting activatorsINCYTE CORP·Filed 2019·Granted Mar 16, 2021·5 cites·35 claims
- 1081US2023192689A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2023·Application pending·0 cites
- 1179US12466828B2Bicyclic amines as CDK2 inhibitorsINCYTE CORP·Filed 2023·Granted Nov 11, 2025·0 cites·47 claims
- 1271US2023398225A1Pd-l1/sting conjugates and methods of useINCYTE CORP·Filed 2023·Application pending·0 cites
- 1370US2023226062A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2022·Application pending·0 cites
- 1469US2025188073A1Tricyclic compounds as inhibitors of krasINCYTE CORP·Filed 2024·Application pending·0 cites
- 1569US2020172541A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Application pending·0 cites
- 1665US11401272B2Heterocyclic compounds as LSD1 inhibitorsINCYTE CORP·Filed 2020·Granted Aug 2, 2022·0 cites·31 claims
- 1764US12466822B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2021·Granted Nov 11, 2025·0 cites·28 claims
- 1862US2019071439A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2018·Application pending·0 cites
- 1962US2019144439A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2018·Application pending·0 cites
- 2060US2025195484A1Cereblon ligands and uses thereofUNIV MICHIGAN·Filed 2023·Application pending·0 cites
- 2159US2017320875A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 2259US2025243152A1Intermediate of polyamine derivative pharmaceutical salt, preparation method therefor, and use thereofWUHAN WUYAO SCI & TECH CO LTD·Filed 2023·Application pending·0 cites
- 2358US2021269434A1Tricyclic compounds as inhibitors of krasINCYTE CORP·Filed 2021·Application pending·0 cites
- 2458US2025230126A1Intermediate of polyamine derivative, preparation method therefor, and use thereofWUHAN WUYAO SCI&TECH CO LTD·Filed 2022·Application pending·0 cites
- 2557US2017107216A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2016·Application pending·0 cites
- 2657US2018177784A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 2755US2018179202A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 2826US9676788B2Aza-epoxy-guaiane derivatives and treatment of cancerUS HEALTH·Filed 2015·Granted Jun 13, 2017·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when Zhenwu Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →